PARP1 mRNA Biomarkers in CSPC
By Emmanuel Antonarakis, MD - Last Updated: March 31, 2025Emmanuel Antonarakis, MD, of the Masonic Cancer Center at the University of Minnesota, discusses his study presented at ASCO GU 2024 on the use of PARP1 mRNA expression as a prognostic biomarker of aggressive disease and a predictor of response to PARP inhibition for patients with castration-sensitive prostate cancer.
Advertisement
He elaborates on the differences between PARP1 mRNA expression and other biomarkers currently used for risk stratification in this patient population, as well as how it can be used in the clinical decision-making process for patients.
Advertisement
Related Posts
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.